Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Tóm tắt
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute–sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.
Từ khóa
Tài liệu tham khảo
Cheson, 1988, Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL): recommendations of the NCI-sponsored working group., Am J Hematol, 29, 153, 10.1002/ajh.2830290307
Cheson, 1996, National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment., Blood, 87, 4990, 10.1182/blood.V87.12.4990.bloodjournal87124990
Müller-Hermelink, 2001, Chronic lymphocytic leukemia/small lymphocytic lymphoma., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 127
Catovsky, 2001, T-cell prolymphocytic leukaemia., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 195
Melo, 1986, The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia: IV. Analysis of survival and prognostic features., Br J Haematol, 63, 377, 10.1111/j.1365-2141.1986.tb05563.x
Marti, 2005, Diagnostic criteria for monoclonal B-cell lymphocytosis., Br J Haematol, 130, 325, 10.1111/j.1365-2141.2005.05550.x
Rawstron, 2008, Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia (CLL)., N Engl J Med, 359, 575, 10.1056/NEJMoa075290
Moreau, 1997, Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b)., Am J Clin Pathol, 108, 378, 10.1093/ajcp/108.4.378
Ginaldi, 1998, Levels of expression of CD19 and CD20 in chronic B cell leukaemias., J Clin Pathol, 51, 364, 10.1136/jcp.51.5.364
Catovsky, 2001, B-cell prolymphocytic leukaemia., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 131
Döhner, 2000, Genomic aberrations and survival in chronic lymphocytic leukemia., N Engl J Med, 343, 1910, 10.1056/NEJM200012283432602
Mayr, 2006, Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia., Blood, 107, 742, 10.1182/blood-2005-05-2093
Döhner, 1995, p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias., Blood, 85, 1580, 10.1182/blood.V85.6.1580.bloodjournal8561580
Grever, 2007, Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997., J Clin Oncol, 25, 799, 10.1200/JCO.2006.08.3089
Stilgenbauer, 2002, Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy., N Engl J Med, 347, 452, 10.1056/NEJM200208083470619
Lozanski, 2004, Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions., Blood, 103, 3278, 10.1182/blood-2003-10-3729
Shanafelt, 2006, Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia., J Clin Oncol, 24, 4634, 10.1200/JCO.2006.06.9492
Damle, 1999, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments]., Blood, 94, 1840, 10.1182/blood.V94.6.1840
Hamblin, 1999, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments]., Blood, 94, 1848, 10.1182/blood.V94.6.1848
Thorselius, 2006, Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status., Blood, 107, 2889, 10.1182/blood-2005-06-2227
Orchard, 2004, ZAP-70 expression and prognosis in chronic lymphocytic leukaemia., Lancet, 363, 105, 10.1016/S0140-6736(03)15260-9
Crespo, 2003, ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia., N Engl J Med, 348, 1764, 10.1056/NEJMoa023143
Rassenti, 2004, ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia., N Engl J Med, 351, 893, 10.1056/NEJMoa040857
Ibrahim, 2001, CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia., Blood, 98, 181, 10.1182/blood.V98.1.181
Lin, 2002, Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia., Blood, 100, 1404, 10.1182/blood-2001-11-0066
Ghia, 2003, The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression., Blood, 101, 1262, 10.1182/blood-2002-06-1801
Boonstra, 2006, CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression., Cytometry B Clin Cytom, 70, 136, 10.1002/cyto.b.20106
Byrd, 2006, Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy., J Clin Oncol, 24, 437, 10.1200/JCO.2005.03.1021
Hallek, 1999, Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progression in early, non-smoldering chronic lymphocytic leukemia., Blood, 93, 1732
Keating, 1995, The serum β2-microglobulin (β2m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL)., Blood, 86, 606a
Reinisch, 1994, Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia., J Clin Oncol, 12, 2146, 10.1200/JCO.1994.12.10.2146
Sarfati, 1996, Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia., Blood, 88, 4259, 10.1182/blood.V88.11.4259.4259
Wierda, 2007, Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia., Blood, 109, 4679, 10.1182/blood-2005-12-051458
Magnac, 2003, Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL., Leukemia, 17, 133, 10.1038/sj.leu.2402780
Matthews, 2006, Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression., Eur J Haematol, 77, 309, 10.1111/j.1600-0609.2006.00707.x
Bergmann, 2007, Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): results of the CLL1-Protocol of the German CLL Study Group (GCLLSG)., Blood (ASH Annual Meeting Abstracts), 110, 625
Rai, 1975, Clinical staging of chronic lymphocytic leukemia., Blood, 46, 219, 10.1182/blood.V46.2.219.bloodjournal462219
Binet, 1981, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis., Cancer, 48, 198, 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V
Rai, 1987, A critical analysis of staging in CLL., Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, 253
Extermann, 1998, Comorbidity and functional status are independent in older patients., J Clin Oncol, 16, 1582, 10.1200/JCO.1998.16.4.1582
Balducci, 2000, Management of cancer in the older person: a practical approach., Oncologist, 5, 224, 10.1634/theoncologist.5-3-224
O'Brien, 2006, Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab., Clin Lymphoma Myeloma, 7, 125, 10.3816/CLM.2006.n.049
Yagci, 2006, A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues., Leuk Lymphoma, 47, 1608, 10.1080/10428190500472974
Rossi, 2001, Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy., Br J Haematol, 115, 58, 10.1046/j.1365-2141.2001.03099.x
Muntanola, 2007, Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia., J Clin Oncol, 25, 1576, 10.1200/JCO.2006.08.4194
Dighiero, 1998, Chlorambucil in indolent chronic lymphocytic leukemia., N Engl J Med, 338, 1506, 10.1056/NEJM199805213382104
Shustik, 1988, Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation., Hematol Oncol, 6, 7, 10.1002/hon.2900060103
Montserrat, 1991, Chronic lymphocytic leukemia treatment: an interim report of PETHEMA trials., Leuk Lymphoma, 5, 89, 10.3109/10428199109103385
CLL Trialists' Collaborative Group, 1999, Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials., J Natl Cancer Inst, 91, 861, 10.1093/jnci/91.10.861
Moreno, 2005, Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia., J Clin Oncol, 23, 3433, 10.1200/JCO.2005.04.531
Dreger, 2005, Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis., Leukemia, 19, 1029, 10.1038/sj.leu.2403745
Gribben, 2005, Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia., Blood, 106, 4389, 10.1182/blood-2005-05-1778
Schetelig, 2003, Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group., J Clin Oncol, 21, 2747, 10.1200/JCO.2003.12.011
Caballero, 2005, Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)., Clin Cancer Res, 11, 7757, 10.1158/1078-0432.CCR-05-0941
Oudat, 2002, Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission., Leukemia, 16, 632, 10.1038/sj.leu.2402439
Noy, 2001, Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol., Blood, 97, 1929, 10.1182/blood.V97.7.1929
Cheson, 2007, Revised response criteria for malignant lymphoma., J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403
Blum, 2007, Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria., J Clin Oncol, 25, 5624, 10.1200/JCO.2007.12.1152
Dreger, 2007, Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus., Leukemia, 21, 12, 10.1038/sj.leu.2404441
Rawstron, 2007, International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia., Leukemia, 21, 956, 10.1038/sj.leu.2404584
Moreton, 2005, Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival., J Clin Oncol, 23, 2971, 10.1200/JCO.2005.04.021
Wendtner, 2004, Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)., Leukemia, 18, 1093, 10.1038/sj.leu.2403354
Bosch, 2002, Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia., Br J Haematol, 119, 976, 10.1046/j.1365-2141.2002.03959.x
Eichhorst, 2007, Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy., Br J Haematol, 136, 63, 10.1111/j.1365-2141.2006.06382.x
Cheson, 1998, Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia., J Clin Oncol, 16, 2313, 10.1200/JCO.1998.16.7.2313
National Cancer Institute Common Toxicity Criteria and Common Terminology Criteria for Adverse Events. Accessed April 15, 2008 http://ctep.cancer.gov/reporting/ctc.html
Eichhorst, 2007, Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group., J Clin Oncol, 25, 1722, 10.1200/JCO.2006.05.6929
Molica, 2005, Quality of life in chronic lymphocytic leukemia: a neglected issue., Leuk Lymphoma, 46, 1709, 10.1080/10428190500244183
Holzner, 2004, Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr., Eur J Haematol, 72, 381, 10.1111/j.1600-0609.2004.00233.x
Levy, 2001, Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis., J Clin Epidemiol, 54, 747, 10.1016/S0895-4356(00)00359-0
Ozer, 2000, 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel., J Clin Oncol, 18, 3558, 10.1200/JCO.2000.18.20.3558
Ludwig, 2002, Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations., Hematol J, 3, 121, 10.1038/sj.thj.6200160
Lichtin, 2005, The ASH/ASCO clinical guidelines on the use of erythropoietin., Best Pract Res Clin Haematol, 18, 433, 10.1016/j.beha.2005.01.020
Rodon, 2003, Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H., Eur J Haematol, 70, 319, 10.1034/j.1600-0609.2003.00055.x
Hamblin, 2006, Autoimmune complications of chronic lymphocytic leukemia., Semin Oncol, 33, 230, 10.1053/j.seminoncol.2006.01.011
Zaja, 2003, Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases., Leuk Lymphoma, 44, 1951, 10.1080/1042819031000119235